Anti-HIV Therapy Update
Several new anti-HIV therapies have recently entered human studies. Most of these drugs belong to the currently existing classes of therapies (i.e., protease inhibitors or non-nucleoside reverse transcriptase inhibitors). Laboratory studies suggest that their resistance patterns are different from the existing drugs and so may be effective against drug-resistant viruses, rendering them of potential interest for people seeking third line therapy options.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)Tibotec, a new company based in Belgium, reported results from a small study of their new NNRTI, TMC-120. In laboratory study, this drug remains sensitive to virus that are resistant to the currently approved NNRTIs. However, this initial human study was conducted among people who had not previously received anti-HIV therapies, and so it is not known how effective this drug really is for people who are resistant to current NNRTIs.
Forty-three people with an average viral load of about 32,000 copies and CD4+ cell counts of about 600 participated in this study. Participants received 50mg of TMC-120 twice a day, 100mg of TMC-120 twice a day or placebo for seven days, after which everybody received three-drug therapy. There was essentially no difference in viral load or CD4+ cell count response between the two doses of TMC-120, with about a one and a half log (32 times) reduction in viral load. CD4+ cell increases of 120 were seen at the end of the seven days.
One of the primary concerns with the NNRTIs is the potential for rapid development of resistance, especially when used alone or part of a sub-optimal regimen. No resistance was found among any of the individuals at the end of this study.
Nevertheless, the true test for this drug will be in how effective it is for people who have developed resistance to the current NNRTIs. Only when those studies are conducted will we learn whether this drug is really different from what is currently available.
The future of the new NNRTI capravirine is up in the air. Laboratory studies suggesting long-term side effects in some animals have put future studies on temporary hold. Inflammation of the blood vessels (vasculitis) was seen in some animals receiving a high dose of the drug. This has not been observed in any of the human studies of capravirine.
Preliminary results were reported from a study of capravirine in people who were experiencing increases in viral load while on a NNRTI-based regimen. The 61 participants had an average viral load of about 10,000 copies HIV RNA and CD4+ cell count of about 300 at the start of the study. No one had previously used a protease inhibitor. All of the volunteers received nelfinavir (Viracept) + two new nucleoside drugs and 1,400mg or 2,100mg of capravirine twice a day or placebo. There was little difference in response rates after sixteen weeks among the three groups with 60-75% of participants having viral loads below 400 copies HIV RNA. However, people receiving capravirine experienced more side effects (diarrhea), especially those receiving the higher dose. Based on this small short-term study, it is difficult to determine exactly how much, if any, capravirine is contributing to the overall anti-HIV response.
Fusion InhibitorsNew results from a study involving T-20 (pentafuside) continue to show that the drug might be useful for people constructing a third line regimen. Seventy-one people with an average viral load of about 20,000 copies HIV RNA and CD4+ cell counts of about 230 received abacavir (Ziagen) + efavirenz (Sustiva) + ritonavir (Norvir) + amprenavir (Agenerase) with or without T-20. The dose of ritonavir and amprenavir used in this study was 200mg and 1,200mg respectively both taken twice a day and the dose for T-20 were 50mg, 75mg or 100mg all dosed twice a day by injection under the skin (subcutaneous). All of the participants had previously taken a protease inhibitor but not a NNRTI.
The results of the three T-20 doses were pooled together and after 16 weeks of the study 71% of people receiving T-20 had viral loads below 400 copies HIV RNA compared to 58% for those not receiving the drug. The percentage of people with viral load below 50 copies HIV RNA was 48% for those receiving T-20 and 37% for those not receiving the drug. Additionally, volunteers receiving T-20 had about a 50 CD4+ cell count increase whereas there was no change in CD4+ cell counts for those not receiving the drug.
A small expanded access program for T-20 should open within the next few months for people needing the drug to construct a third line regimen. Watch for announcements about the program and when you hear it, call the Project Inform Hotline to get the details on how to apply.
A second generation fusion inhibitor is now being studied. In laboratory studies T-1249 remains sensitive to virus that have developed resistance to T-20. Preliminary results from a small study shows that the drug does have activity against HIV; however, there were also a large number of mild-to-moderate side effects.
Seventy-two people with an average viral load of about 100,000 copies HIV RNA and CD4+ cell counts of 100 participated in this study. Almost all of the participants had been on previous anti-HIV therapies. Six different doses were studied ranging from 6.25mg once a day to 25mg twice a day all dosed by subcutaneous injection. Volunteers receiving the highest dose had an average 1.3 log (20 times) reduction in viral load after 14 days on the drug. Side effects included injection site reaction (mostly pain or redness in the skin), headaches and dizziness. Two serious side effects were observed, a hypersensitivity reaction to the drug and neutropenia (a reduction in neutrophils, a type of white blood cell used to fight infections).
Protease InhibitorsIt is not clear whether the new protease inhibitor BMS-232632 will be effective against viruses resistant to the currently approved protease inhibitors. Nevertheless, one apparent benefit of the drug is there have been no reports of increases in triglyceride or cholesterol levels among people taking it.
The study enrolled 420 people with an average viral load of 50,000 copies HIV RNA and CD4+ cell counts of about 350. None of the participants had previously received anti-HIV therapies. All the volunteers received d4T (stavudine, Zerit) + ddI (didanosine, Videx) and either 200mg, 400mg, 500mg of BMS-232632 once a day or 750mg of nelfinavir (Viracept) dosed three times a day. Results were similar for all four groups with 63-68% of the participants achieving viral loads under 400 copies HIV RNA after 24 weeks and about 100 cell increase in CD4+ cell counts. Participants receiving nelfinavir had increases in cholesterol and triglyceride levels whereas those receiving BMS-232632 had no changes in either of these markers. A number of people had to reduce from the 500mg to the 400mg dose primarily because of an increase in bilirubin levels, a measure of liver function. As a result of this, future studies will be using the 400mg once a day dose.
CommentaryPeople who have exhausted their treatment options need new potent drugs, especially those that are effective against drug-resistant virus. Studies of these newer drugs suggest that they will offer some improvement over the current drugs. Furthermore, newer classes of drugs have recently entered studies, including drugs that block the chemokine receptors CCR5 and CXCR4, two "pathways" that HIV uses to infect cells.
This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.